Jinxin Fertility Group Limited (JXR, stock code: 01951) has reported that the new campus of its Shenzhen Zhongshan Obstetrics and Gynecology Hospital commenced trial operations on February 6, 2026. The facility, located in Shenzhen’s central area, spans approximately 0.04 million square meters, nearly four times the size of the original campus. According to the announcement, this expansion provides a solid foundation for continued growth, with specialized VIP services, distinctive specialties, and an international medical department planned at the site. The group’s Shenzhen operations recorded an 18% increase in oocyte pick-up cycles (OPU Cycles) during the first two months of 2026 compared to the same period in 2025.

In the United States, the HRC Fertility clinics controlled by JXR through management service agreements showed a 38% jump in OPU Cycles during the first two months of 2026 as opposed to the same period in 2025. The announcement attributes this growth primarily to growing local demand following the official implementation in January 2026 of California’s IVF insurance coverage under Senate Bill 729 (SB729). Under this coverage, large-corporate plans must include infertility diagnosis and treatment benefits, offering three completed OPU cycles, unlimited embryo transfers, and equitable access for patients of various backgrounds.

The announcement highlights that JXR remains focused on operational optimization, clinical quality, and accelerated development of core reproductive technologies. The group aims to enhance patient care and service standards to deliver sustainable, long-term value while contributing to high-quality industry growth. All reported figures are based on the group’s preliminary assessments, and shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.